Risk of <i>Candida</i> Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

<div>Forest plot of pooled data regarding <i>Candida</i> infections between anti-interleukin (IL)-17 agents and tumor necrosis factor inhibitors (TNFi). CI, confidence interval.</div>

International Journal of Clinical Practice

fig4

Figure 4

Figure 4: Risk of <i>Candida</i> Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 

Figure 4 | Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 